New pancreatic cancer drug hailed as ‘closest thing to a cure’ - The Independent

Direct Source Verification: This story is aggregated from The Independent (independent.co.uk). Full reporting rights and copyright belong to the primary publisher.
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today.

A new once-a-day pill for advanced pancreatic cancer has wiped out the disease in one in 12 patients when combined with chemotherapy, a clinical trial suggests.

The study, which was presented at the European Organisation for Research and Treatment of Cancer in Barcelona, found that combining the drug daraxonrasib with chemotherapy increased the proportion of patients alive after one year compared to standard treatment.

The lead medic on the trial said the results represented the “closest” thing to a “cure” for some patients.

Daraxonrasib made headlines in May after it was found to almost double survival time for patients with aggressive and advanced pancreatic cancer when compared to chemotherapy alone. It also caused fewer side effects.

The drug works by locking onto the mutated KRAS gene, which is found in more than nine in 10 pancreatic tumours and continuously signals cancer cells to grow.

By shutting this off, the drug can prevent tumours from spreading.

In the new study, tumours shrank or disappeared in 60.7 per cent of patients given daraxonrasib and chemotherapy.

This included complete responses in 8.2 per cent of patients over a typical follow-up of 18 months, meaning their tumours were no longer detectable.

Overall, tumours stopped growing in 90.2 per cent of the 61 patients studied (the disease control rate) over a typical period of 18 months.

One year after treatment, 76.6 per cent of patients were still alive. This compares to around 40 to 45 per cent of patients when they are given chemotherapy alone.

It also took 12.8 months on average for tumours to return or start growing again when the whole patient group was taken into account, the phase one/two clinical trial showed.

Dr Wungki Park, oncologist at Memorial Sloan Kettering Cancer Centre in New York, who presented the findings, said he had never seen such responses, adding it represents “a massive, massive breakthrough” in treating pancreatic cancer.

“In about one in 12 patients, it (the cancer) completely disappeared,” he said.

“And then with such a long follow-up, this is real. We’ve never seen such a thing.”

Asked if the one in 12 patients whose tumours could not be seen were regarded as cured, he said: “This is the closest to cure.

“This is almost at the discovery level; we have never seen eight per cent complete response in metastatic pancreatic cancer, you don’t see that….

“The median follow-up is 18 months. Just imagine, in an average of 18 months your disease just disappears on the CT scan … that’s closest to complete remission …. it’s incredible.”

He said longer-term survival data would come as the trial progressed, but there is “some survival signal here, which is very strong”, with 76.6 per cent of patients alive after one year.

Fewer than five per cent of patients in the trial discontinued treatment, which is regarded as low.

Dr Park said cancer does frequently develop resistance to drug treatment but “we’re delaying that as much as possible” through the new combined treatment.

The final phase-three study in the US has enough patients but some sites in Europe may have space.

Original Source
https://www.independent.co.uk/news/health/pancreatic-cancer-pill-drug-daraxonrasib-symptoms-uk-b3088527.html
Visit The Independent ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health